STXS_OUT_1 [2025-03-19 15:51:46 -0400] 1974 Bytes | 572 tokens | Cum: 572 tkns (7.15% of 8k)
==========================================================================

Alright, let’s light it up, because it's 03:51:45 PM on Wednesday March 19, 2025 ET (UTC-0400), and I'm charging into Stereotaxis (STXS), popping from 1.85 to 2.135. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

Here's the first list of news for Stereotaxis:

C1 - Today 08:01AM - Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program
C2 - Mar-10-25 08:02AM - Stereotaxis to Present at 37th Annual Roth Conference
C3 - Mar-04-25 07:45AM - Stereotaxis sees double digit revenue growth for FY25
C4 - Mar-04-25 07:45AM 07:40AM - Stereotaxis submits EMAGIN catheter for regulatory clearance
C5 - Mar-04-25 07:45AM 07:36AM - Stereotaxis announces FDA regulatory submission for MAGiC Sweep catheter
C6 - Mar-04-25 07:45AM 02:01AM - Stereotaxis Inc (STXS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...
C7 - Mar-04-25 07:45AM 12:34AM - Q4 2024 Stereotaxis Inc Earnings Call
C8 - Mar-03-25 08:45AM - Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about Stereotaxis (STXS)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of Stereotaxis.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

STXS_OUT_3 [2025-03-19 15:51:50 -0400] 969 Bytes | 266 tokens | Cum: 840 tkns (10.50% of 8k)
==========================================================================

Showing C1 (chunk 1 of 6): C1:
**Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program**
Date: Today 08:01AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/19/3045343/21634/en/Stereotaxis-Highlighted-by-NVIDIA-at-GTC-Artificial-Intelligence-Conference-and-Accepted-into-NVIDIA-Connect-Program.html

March 19, 2025 08:01 ET| Source:Stereotaxis, Inc.Stereotaxis, Inc.

ST. LOUIS, March 19, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that NVIDIA highlighted Stereotaxis’ technology at NVIDIA GTC and has accepted Stereotaxis into the NVIDIA Connect program.

NVIDIA GTC (GPU Technology Conference) is a global artificial intelligence (AI) conference that brings together engineers, researchers, and inventors

-- More? (MOR) or Next section? (NEX)

STXS_OUT_5 [2025-03-19 15:51:51 -0400] 977 Bytes | 195 tokens | Cum: 1037 tkns (12.96% of 8k)
==========================================================================

Showing C1 (chunk 2 of 6): working to pioneer applications for AI. This year’s conference has brought together over 25,000 attendees in San Jose this week. At a special address by NVIDIA’s Vice President of Healthcare and Life Sciences, NVIDIA highlighted Stereotaxis’ surgical robots and the efforts to incorporate AI into robotics heralding a new chapter in medical progress. NVIDIA also recently accepted Stereotaxis into its NVIDIA Connect program, which supports member companies with NVIDIA’s software development resources, industry-leading frameworks and software development kits.

Stereotaxis’ robotic technologies are at the forefront of efforts to advance robotics in minimally-invasive endovascular surgeries. Its robots have already been used by physicians at over 100 leading hospitals globally to treat over 150,000 patients. As Stereotaxis nears completion of its initial wave of core innovations in robotics a

-- More? (MOR) or Next section? (NEX)

STXS_OUT_7 [2025-03-19 15:51:53 -0400] 981 Bytes | 195 tokens | Cum: 1234 tkns (15.43% of 8k)
==========================================================================

Showing C1 (chunk 3 of 6): nd interventional devices, it has set its sights on the next phase of technological progress. This includes a pronounced focus on digital solutions that enhance its robotic systems and the operating room environment with artificial intelligence, robotic automation, data integration and decision support capabilities. Stereotaxis has already begun meaningful investments in these efforts.

“We greatly appreciate the support of NVIDIA in our efforts to pioneer endovascular robotics and take the technology to new incredible heights,” said David Fischel, Stereotaxis Chairman & CEO. “The combination of robotics’ mechanistic benefits – precision, safety, stability – with the promise of AI innovations will dramatically transform what is possible in treating patients. We are excited for the path ahead of us.”

About StereotaxisStereotaxis (NYSE: STXS) is a pioneer and global leader in innovative s

-- More? (MOR) or Next section? (NEX)

STXS_OUT_9 [2025-03-19 15:51:55 -0400] 974 Bytes | 283 tokens | Cum: 1519 tkns (18.99% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-19T16:28:30Z - TD Cowen Reiterates Buy Rating on Stereotaxis (STXS)...
A2 - 2025-03-19T12:23:28Z - Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA...
A3 - 2025-03-19T12:15:32Z - Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA...
A4 - 2025-03-19T12:09:24Z - Stereotaxis (STXS) Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into...
A5 - 2025-03-12T20:31:24Z - Paul J. Isaac Acquires 38,000 Shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS) Stock...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

STXS_OUT_11 [2025-03-19 15:52:02 -0400] 667 Bytes | 197 tokens | Cum: 1718 tkns (21.48% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
**TD Cowen Reiterates Buy Rating on Stereotaxis (STXS)**Date: 2025-03-19Source: {'uri': 'streetinsider.com', 'dataType': 'news', 'title': 'StreetInsider.com'}URL: https://www.streetinsider.com/AI/TD+Cowen+Reiterates+Buy+Rating+on+Stereotaxis+%28STXS%29/24522125.htmlTD Cowen analyst Joshua Jennings reiterated a Buy rating and $5.00 price target on Stereotaxis (NYSE: STXS).The analyst comments "STXS's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

-- More? (MOR) or Next section? (NEX)

STXS_OUT_13 [2025-03-19 15:52:04 -0400] 1140 Bytes | 329 tokens | Cum: 2182 tkns (27.27% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-20T08:30:00Z - Global Magnetic Ablation Catheters Market Poised for Significant Growth, Projected to Reach USD 1,114.4 Million by 2035 Driven by Technological Advancements and Rising Cardiovascular Cases | Future Market Insights, Inc.
B2 - 2024-09-05T00:30:00Z - Medical Robots Market Report: Technological Advancements in Medical Industry and Growth of AI to Boosts the Demand | Future Market Insights, Inc.
B3 - 2024-05-29T12:25:00Z - Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
B4 - 2024-05-27T14:50:00Z - Stereotaxis (STXS) Gets CE Recertification for Approved Products
B5 - 2024-05-24T16:34:00Z - Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias
B6 - 2024-05-24T12:37:00Z - Stereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

STXS_OUT_15 [2025-03-19 15:52:10 -0400] 950 Bytes | 234 tokens | Cum: 2418 tkns (30.23% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Global Magnetic Ablation Catheters Market Poised for Significant Growth, Projected to Reach USD 1,114.4 Million by 2035 Driven by Technological Advancements and Rising Cardiovascular Cases | Future Market Insights, Inc.**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/20/3029340/0/en/Global-Magnetic-Ablation-Catheters-Market-Poised-for-Significant-Growth-Projected-to-Reach-USD-1-114-4-Million-by-2035-Driven-by-Technological-Advancements-and-Rising-Cardiovascula.htmlThe global magnetic ablation catheters market is expected to grow significantly, reaching $1.1 billion by 2035, driven by advancements in technology and the rising prevalence of cardiovascular diseases. Key factors driving growth include the increasing adoption of minimally invasive procedures and continued investment in healthcare infrastructure and R&D.

-- More? (MOR) or Next section? (NEX)

STXS_OUT_17 [2025-03-19 15:52:11 -0400] 815 Bytes | 217 tokens | Cum: 2719 tkns (33.99% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-14 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER ##TABLE_END

The following discussion and analysis should be read in conjunction with our CONS financial statements and notes thereto included in this report on Form 10-K. Opera...

S4 - 2025-03-03 8-K Item 2.02 Results of Oper and Fin Cond

On March 3, 2025, Stereotaxis, Inc. (the Company) issued a press release (the Earnings Press Release) setting forth its financial results for the 2024 fourth quarter and full year. A copy of the Earnings Press Release is b...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

STXS_OUT_19 [2025-03-19 15:52:12 -0400] 967 Bytes | 194 tokens | Cum: 2915 tkns (36.44% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ##TABLE_END

The following discussion and analysis should be read in conjunction with our consolidated financial statements and notes thereto included in this report on Form 10-K. Operating results are not necessarily indicative of results that may occur in future periods.

This report includes various forward-looking statements that are subject to risks and uncertainties, many of which are beyond our control. Our actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including those set forth in Item 1A. Risk Factors, as well as various impacts related to our previously announced acquisition of Access Point Technologies EP, Inc. (APT). Forward-looking statements discuss matters that are not historical facts. Forwar

-- More? (MOR) or Next section? (NEX)

STXS_OUT_21 [2025-03-19 15:52:27 -0400] 4272 Bytes | 1179 tokens | Cum: 4096 tkns (51.20% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+--------------------+-----------------------+-------------------------+------------------------+-------------------------+
| Prev Close: 1.85 | RSI (14): 53.51 | Perf Quarter: -10.47% | Insider Trans: 0.41% | Sales Q/Q: 38.88% | ROE: -144.19% |
+---------------------+--------------------+-----------------------+-------------------------+------------------------+-------------------------+
| Target Price: 4.50 | ATR (14): 0.15 | Index: RUT | Option/Short: Yes / Yes | Sales past 5Y: -0.06% | ROI: -150.30% |
+---------------------+--------------------+-----------------------+-------------------------+------------------------+-------------------------+
| Price: 2.10 | SMA20: 5.93% | Market Cap: 177.51M | Short Float: 5.39% | Income: -25.35M | Sales Surprise: -10.39% |
+---------------------+--------------------+-----------------------+-------------------------+------------------------+-------------------------+
| Change: 13.24% | SMA50: -2.94% | Shs Outstand: 85.32M | Short Ratio: 8.19 | Employees: 139 | EPS Surprise: -38.46% |
+---------------------+--------------------+-----------------------+-------------------------+------------------------+-------------------------+
| Volume: 1,326,915 | SMA200: 1.51% | Shs Float: 69.51M | Short Interest: 3.74M | Debt/Eq: 0.53 | P/E: - |
+---------------------+--------------------+-----------------------+-------------------------+------------------------+-------------------------+
| Avg Volume: 456.98K | Perf Week: 14.48% | Inst Own: 49.24% | Beta: 1.58 | Sales Y/Y TTM: 0.55% | Earnings: Mar 03 BMO |
+---------------------+--------------------+-----------------------+-------------------------+------------------------+-------------------------+
| Rel Volume: 3.08 | Perf Month: -3.46% | Insider Own: 17.96% | Sales: 26.92M | Profit Margin: -94.19% | |
+---------------------+--------------------+-----------------------+-------------------------+------------------------+-------------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: Stereotaxis, Inc. (STXS) by Isaac Paul J (Unknown Title) on 2025-03-10
- Common stock: 38000 shares at $1.81 (D)

Inside Trans: Stereotaxis, Inc. (STXS) by Isaac Paul J (Unknown Title) on 2025-03-06
- Common stock: 23299 shares at $1.81 (D)
- Common stock: 1489 shares at $1.79 (I)

Inside Trans: Stereotaxis, Inc. (STXS) by SHAMIR NACHUM (Unknown Title) on 2025-01-02
- Common Stock: 45608 shares at $0 (D)

Inside Trans: Stereotaxis, Inc. (STXS) by Curet Myriam (Unknown Title) on 2025-01-02
- Common Stock: 56497 shares at $0 (D)

Inside Trans: Stereotaxis, Inc. (STXS) by Benfer David (Unknown Title) on 2025-01-02
- Common Stock: 56497 shares at $0 (D)

Inside Trans: Stereotaxis, Inc. (STXS) by Fischel Nathan (Unknown Title) on 2025-01-02
- Common Stock: 56497 shares at $0 (D)

Inside Trans: Stereotaxis, Inc. (STXS) by Menawat Arun Swarup (Unknown Title) on 2025-01-02
- Common Stock: 56497 shares at $0 (D)

Inside Trans: Stereotaxis, Inc. (STXS) by Levin Ross B (Unknown Title) on 2025-01-02
- Common Stock: 56497 shares at $0 (D)

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

STXS_OUT_23 [2025-03-19 15:52:33 -0400] 561 Bytes | 131 tokens | Cum: 4549 tkns (56.86% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

STXS_IN_25 [2025-03-19 15:52:34 -0400] 126 Bytes | 29 tokens | Cum: 4678 tkns (58.48% of 8k)
==========================================================================

====================================
[2025-03-19 12:52:34] # Analysis Completed
Elapsed Time: 49.48 seconds